ArticleFrontiers in pediatrics2017
Impact of Fecal Calprotectin Measurement on Decision-making in Children with Inflammatory Bowel Disease.
Article in Frontiers in pediatrics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03262649 (Manitoba Inflammatory Bowel Disease Cohort Study), which is not on this map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Manitoba Inflammatory Bowel Disease Cohort Study
Who cites it
10 citing papers in PubMed, 18 citations in OpenAlex.
- Treatment escalation and de-escalation decisions in Crohn's disease: Delphi consensus recommendations from Japan, 2021.Journal of gastroenterology · 2023Review
- Role of B-Cell Activating Factor (BAFF) in Inflammatory Bowel Disease.Diagnostics (Basel, Switzerland) · 2021Review
- Timely Monitoring of Inflammation by Fecal Lactoferrin Rapidly Predicts Therapeutic Response in Inflammatory Bowel Disease.Inflammatory bowel diseases · 2021Article
- B cell-activating factor (BAFF) in children with inflammatory bowel disease.Pediatric research · 2021Article
- Fecal Lactoferrin Predicts Primary Nonresponse to Biologic Agents in Inflammatory Bowel Disease.Digestive diseases (Basel, Switzerland) · 2021Article
- The reduction of faecal calprotectin during exclusive enteral nutrition is lost rapidly after food re-introduction.Alimentary pharmacology & therapeutics · 2019Observational
- Impact of faecal calprotectin measurement on clinical decision-making in patients with Crohn's disease and ulcerative colitis.PloS one · 2019Article
- Commentary: Impact of Fecal Calprotectin Measurement on Decision-Making in Children with Inflammatory Bowel Disease.Frontiers in pediatrics · 2017Article
- Assessing the correlation between fecal calprotectin, blood markers and disease activity in pediatric inflammatory bowel disease.Annals of gastroenterologyArticle
- Clinical Performance of Fecal Calprotectin Reagents Based on the Colloidal Gold Agglutination Method for Evaluating the Differential Diagnosis between Inflammatory Bowel Disease and Irritable Bowel Syndrome in Adults and Children with Gastrointestinal Symptoms (SCALE 1).Inflammatory intestinal diseasesArticle
Corrections and comments
- Commented on by
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe use of fecal calprotectin (FCal) as a marker of intestinal inflammation, in the management of inflammatory bowel disease (IBD) is increasing. The aim of this study was to examine the impact of FCal measurements on decision-making and clinical care of children with IBD. MATERIALS AND
methodsIn a retrospective cohort study, FCal, clinical activity indices, and blood markers were measured in children with established diagnoses of IBD. Pearson correlation coefficient analysis was performed to examine association between FCal and other markers. Decisions based on FCal measurements were prospectively documented and participants were evaluated 3-6 months later.
resultsA total of 115 fecal samples were collected from 77 children with IBD [median age 14, interquartile range (IQR) 11-15.6 years, 42 females, 37 with Crohn's disease]. FCal positively correlated with clinical activity indices (
conclusionBased on high FCal, the majority of children had treatment escalation that resulted in clinical improvement. FCal measurements were useful and reliable in decision-making and clinical care of children with IBD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.